422 related articles for article (PubMed ID: 29183995)
1. Deubiquitylase USP9X suppresses tumorigenesis by stabilizing large tumor suppressor kinase 2 (LATS2) in the Hippo pathway.
Zhu C; Ji X; Zhang H; Zhou Q; Cao X; Tang M; Si Y; Yan H; Li L; Liang T; Feng XH; Zhao B
J Biol Chem; 2018 Jan; 293(4):1178-1191. PubMed ID: 29183995
[TBL] [Abstract][Full Text] [Related]
2. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3 ligase.
Ma B; Chen Y; Chen L; Cheng H; Mu C; Li J; Gao R; Zhou C; Cao L; Liu J; Zhu Y; Chen Q; Wu S
Nat Cell Biol; 2015 Jan; 17(1):95-103. PubMed ID: 25438054
[TBL] [Abstract][Full Text] [Related]
4. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
Hao Y; Chun A; Cheung K; Rashidi B; Yang X
J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
[TBL] [Abstract][Full Text] [Related]
5. Sphingosylphosphorylcholine regulates the Hippo signaling pathway in a dual manner.
Kemppainen K; Wentus N; Lassila T; Laiho A; Törnquist K
Cell Signal; 2016 Dec; 28(12):1894-1903. PubMed ID: 27634386
[TBL] [Abstract][Full Text] [Related]
6. Ski regulates Hippo and TAZ signaling to suppress breast cancer progression.
Rashidian J; Le Scolan E; Ji X; Zhu Q; Mulvihill MM; Nomura D; Luo K
Sci Signal; 2015 Feb; 8(363):ra14. PubMed ID: 25670202
[TBL] [Abstract][Full Text] [Related]
7. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway.
Meng Z; Moroishi T; Mottier-Pavie V; Plouffe SW; Hansen CG; Hong AW; Park HW; Mo JS; Lu W; Lu S; Flores F; Yu FX; Halder G; Guan KL
Nat Commun; 2015 Oct; 6():8357. PubMed ID: 26437443
[TBL] [Abstract][Full Text] [Related]
8. The Hippo pathway kinase Lats2 prevents DNA damage-induced apoptosis through inhibition of the tyrosine kinase c-Abl.
Reuven N; Adler J; Meltser V; Shaul Y
Cell Death Differ; 2013 Oct; 20(10):1330-40. PubMed ID: 23852372
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
10.
Kim E; Kang JG; Kang MJ; Park JH; Kim YJ; Kweon TH; Lee HW; Jho EH; Lee YH; Kim SI; Yi EC; Park HW; Yang WH; Cho JW
Proc Natl Acad Sci U S A; 2020 Jun; 117(25):14259-14269. PubMed ID: 32513743
[TBL] [Abstract][Full Text] [Related]
11. Zyxin-Siah2-Lats2 axis mediates cooperation between Hippo and TGF-β signalling pathways.
Ma B; Cheng H; Gao R; Mu C; Chen L; Wu S; Chen Q; Zhu Y
Nat Commun; 2016 Mar; 7():11123. PubMed ID: 27030211
[TBL] [Abstract][Full Text] [Related]
12. CADM1 associates with Hippo pathway core kinases; membranous co-expression of CADM1 and LATS2 in lung tumors predicts good prognosis.
Ito T; Nakamura A; Tanaka I; Tsuboi Y; Morikawa T; Nakajima J; Takai D; Fukayama M; Sekido Y; Niki T; Matsubara D; Murakami Y
Cancer Sci; 2019 Jul; 110(7):2284-2295. PubMed ID: 31069869
[TBL] [Abstract][Full Text] [Related]
13. An evolutionarily conserved negative feedback mechanism in the Hippo pathway reflects functional difference between LATS1 and LATS2.
Park GS; Oh H; Kim M; Kim T; Johnson RL; Irvine KD; Lim DS
Oncotarget; 2016 Apr; 7(17):24063-75. PubMed ID: 27006470
[TBL] [Abstract][Full Text] [Related]
14. The characterisation of LATS2 kinase regulation in Hippo-YAP signalling.
Hoa L; Kulaberoglu Y; Gundogdu R; Cook D; Mavis M; Gomez M; Gomez V; Hergovich A
Cell Signal; 2016 May; 28(5):488-497. PubMed ID: 26898830
[TBL] [Abstract][Full Text] [Related]
15. LATS2 condensates organize signalosomes for Hippo pathway signal transduction.
Qin M; Geng E; Wang J; Yu M; Dong T; Li S; Zhang X; Lin J; Shi M; Li J; Zhang H; Chen L; Cao X; Huang L; Wang M; Li Y; Yang XP; Zhao B; Sun S
Nat Chem Biol; 2024 Jun; 20(6):710-720. PubMed ID: 38200110
[TBL] [Abstract][Full Text] [Related]
16. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
[TBL] [Abstract][Full Text] [Related]
17. The nonreceptor tyrosine kinase c-Src attenuates SCF(β-TrCP) E3-ligase activity abrogating Taz proteasomal degradation.
Shanzer M; Adler J; Ricardo-Lax I; Reuven N; Shaul Y
Proc Natl Acad Sci U S A; 2017 Feb; 114(7):1678-1683. PubMed ID: 28154141
[TBL] [Abstract][Full Text] [Related]
18. Hippo signaling is intrinsically regulated during cell cycle progression by APC/C
Kim W; Cho YS; Wang X; Park O; Ma X; Kim H; Gan W; Jho EH; Cha B; Jeung YJ; Zhang L; Gao B; Wei W; Jiang J; Chung KS; Yang Y
Proc Natl Acad Sci U S A; 2019 May; 116(19):9423-9432. PubMed ID: 31000600
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the Hippo-YAP Pathway by Glucose Sensor O-GlcNAcylation.
Peng C; Zhu Y; Zhang W; Liao Q; Chen Y; Zhao X; Guo Q; Shen P; Zhen B; Qian X; Yang D; Zhang JS; Xiao D; Qin W; Pei H
Mol Cell; 2017 Nov; 68(3):591-604.e5. PubMed ID: 29100056
[TBL] [Abstract][Full Text] [Related]
20. Role of Angiomotin-like 2 mono-ubiquitination on YAP inhibition.
Kim M; Kim M; Park SJ; Lee C; Lim DS
EMBO Rep; 2016 Jan; 17(1):64-78. PubMed ID: 26598551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
